Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas

Relapsed and refractory high-risk neuroblastoma (NBL) patients have limited treatment options and a poor prognosis, highlighting the urgent need for novel targeted therapies. This study evaluates the GD2-targeting PET imaging agent [<sup>89</sup>Zr]Zr-DFO-hu3F8 and the radioimmunotherapy...

全面介绍

Saved in:

书目详细资料
主要作者:	Lingling Zheng (1628176) (author)
其他作者:	Xu Yang (112496) (author), Jun Liu (42548) (author), Guanyun Wang (12750872) (author), Zi Ang Zhou (22687999) (author), Yanfeng Xu (2604343) (author), Jianhua Gong (530290) (author), Jigang Yang (5004701) (author)
出版:	2025
主题:	Biochemistry Medicine Cell Biology Genetics Molecular Biology Physiology Pharmacology Biotechnology Immunology Cancer Computational Biology Biological Sciences not elsewhere classified targeted therapy based novel targeted therapies limited treatment options igg control group biodistribution analysis showed achieving complete remission 47 ± 3 168 h post confirm targeting efficacy 89 </ sup 225 </ sup positive nbl xenografts nbl animal models using [< sup imr32 tumors compared hu3f8 pet imaging 5 kbq ). [< sup vitro </ therapeutic efficacy urgent need tumor uptake sustained uptake study evaluates single dose risk neuroblastoma poor prognosis neuroblastomas relapsed immunopet revealed findings demonstrate
标签:	添加标签没有标签, 成为第一个标记此记录!

Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas

相似书籍